IHT Wealth Management’s Acorda Therapeutics ACOR Stock Holding History

IHT Wealth Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1	Closed	-$2K	–	1459
2018 Q1	$2K	Hold	1	–	–	﹤0.01%	1543
2017 Q4	$2K	Hold	1	–	–	﹤0.01%	1531
2017 Q3	$2K	Hold	1	–	–	﹤0.01%	1252
2017 Q2	$2	Hold	1	–	–	﹤0.01%	1260
2017 Q1	$1K	Hold	1	–	–	﹤0.01%	1231
2016 Q4	$2K	Buy	+1	New	+$2.38K	﹤0.01%	1066

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

IHT Wealth Management's ACOR Position: Q2 2018 in Review

IHT Wealth Management sold out of Acorda Therapeutics (ACOR) in Q2 2018, closing a stake of 1 share — an estimated $2K sold.

IHT Wealth Management first reported a position in ACOR in Q4 2016 and held it in 6 quarters. The position peaked at $2K in Q1 2018. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2018.

IHT Wealth Management reported no remaining Acorda Therapeutics position as of Q2 2018 after selling out during the quarter.
IHT Wealth Management sold 1 Acorda Therapeutics share in Q2 2018, an estimated $2K.
IHT Wealth Management first reported a position in Acorda Therapeutics in Q4 2016 and held it in 6 quarters.
IHT Wealth Management's Acorda Therapeutics position peaked at $2K in Q1 2018.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.